Andreas Argyrides
Stock Analyst at Oppenheimer
(4.31)
# 374
Out of 5,148 analysts
121
Total ratings
50.48%
Success rate
18.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $513.82 | +16.77% | 2 | Feb 26, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $30 → $35 | $17.68 | +97.96% | 15 | Feb 24, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $25.61 | +64.00% | 1 | Jan 22, 2026 | |
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $16.15 | +147.68% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $6.01 | +49.75% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $13.91 | +94.10% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $53.47 | +115.07% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $5.23 | +301.53% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $10.83 | +167.77% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.39 | +8,405.15% | 2 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $3.04 | +394.23% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $20 | $5.06 | +295.26% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $28.90 | +111.07% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $4.21 | +66.27% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $0.92 | +226.05% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $30.94 | -57.98% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.36 | +194.12% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $11.53 | +680.57% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $1.58 | +469.62% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $242.09 | -25.23% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $0.43 | +1,999.86% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $9.17 | +107.20% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $28.61 | +1.36% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $9.24 | +127.27% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $16.32 | +1,272.55% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $21.28 | +167.86% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.06 | +560.38% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.43 | +2,226.12% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $59.74 | +17.17% | 6 | Aug 1, 2023 |
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $575 → $600
Current: $513.82
Upside: +16.77%
MoonLake Immunotherapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $30 → $35
Current: $17.68
Upside: +97.96%
Evommune
Jan 22, 2026
Initiates: Outperform
Price Target: $42
Current: $25.61
Upside: +64.00%
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $16.15
Upside: +147.68%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $6.01
Upside: +49.75%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $13.91
Upside: +94.10%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $53.47
Upside: +115.07%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $5.23
Upside: +301.53%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $10.83
Upside: +167.77%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.39
Upside: +8,405.15%
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $3.04
Upside: +394.23%
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.06
Upside: +295.26%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $28.90
Upside: +111.07%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.21
Upside: +66.27%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.92
Upside: +226.05%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $30.94
Upside: -57.98%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.36
Upside: +194.12%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $11.53
Upside: +680.57%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.58
Upside: +469.62%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $242.09
Upside: -25.23%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $0.43
Upside: +1,999.86%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $9.17
Upside: +107.20%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $28.61
Upside: +1.36%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $9.24
Upside: +127.27%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $16.32
Upside: +1,272.55%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $21.28
Upside: +167.86%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.06
Upside: +560.38%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.43
Upside: +2,226.12%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $59.74
Upside: +17.17%